Integrated analysis of transcriptome and genome variations in pediatric T cell acute lymphoblastic leukemia: data from north Indian tertiary care center

<jats:title>Abstract</jats:title><jats:sec>                 <jats:title>Introduction</jats:title>                 <jats:p>T-cell acute lymphoblastic leukemia (T-ALL) is a genetically heterogeneous disease with poor prognosis and inferior outcome. Although multiple studies have been perform on genomics of T-ALL, data from Indian sub-continent is scarce.</jats:p>               </jats:sec><jats:sec>                 <jats:title>Methods</jats:title>                 <jats:p>In the current study we aimed to identify the genetic variability of T-ALL in an Indian cohort of pediatric (age ≤ 12 years) T-ALL patients (<jats:italic>n</jats:italic> = 25) by whole transcriptome sequencing along with whole exome sequencing and correlated the findings with clinical characteristics and disease outcome.</jats:p>               </jats:sec><jats:sec>                 <jats:title>Results</jats:title>                 <jats:p>The median age was 7 years (range 3 -12 years). RNA sequencing revealed a definitive fusion event in 14 cases (56%) (including a novel fusions) with <jats:italic>STIL::TAL1</jats:italic> in 4 (16%), followed by <jats:italic>NUP21::ABL1, TCF7::SPI1, ETV6::HDAC8, LMO1::RIC3, DIAPH1::JAK2, SETD2::CCDC12</jats:italic> and <jats:italic>RCBTB2::LPAR6</jats:italic> in 1 (4%) case each. Significant aberrant expression was noted in <jats:italic>RAG1</jats:italic> (64%), <jats:italic>RAG2</jats:italic> (80%), <jats:italic>MYCN</jats:italic> (52%), <jats:italic>NKX3-1</jats:italic> (52%),<jats:italic> NKX3-2</jats:italic> (32%), <jats:italic>TLX3 </jats:italic>(28%), <jats:italic>LMO1</jats:italic> (20%) and <jats:italic>MYB</jats:italic> (16%) genes. WES data showed frequent mutations in <jats:italic>NOTCH1</jats:italic> (35%) followed by <jats:italic>WT1</jats:italic> (23%), <jats:italic>FBXW7</jats:italic> (12%), <jats:italic>KRAS</jats:italic> (12%), <jats:italic>PHF6</jats:italic> (12%) and <jats:italic>JAK3</jats:italic> (12%). Nearly 88.2% of cases showed a deletion of <jats:italic>CDKN2A/CDKN2B/MTAP</jats:italic> genes. Clinically significant association of a better EFS and OS (<jats:italic>p</jats:italic>=0.01) was noted with <jats:italic>RAG2</jats:italic> over-expression at a median follow up of 22 months, while a poor EFS (<jats:italic>p</jats:italic>=0.041) and high relapse rate (<jats:italic>p</jats:italic>=0.045) was observed with <jats:italic>MYB</jats:italic> over-expression.</jats:p>               </jats:sec><jats:sec>                 <jats:title>Conclusion</jats:title>                 <jats:p>Overall, the present study demonstrates the frequencies of transcriptomic and genetic alterations from Indian cohort of pediatric T-ALL and is a salient addition to current genomics data sets available in T-ALL.</jats:p>               </jats:sec>

section_content: T-cell acute lymphoblastic leukemia (T-ALL) is a highly aggressive form of ALL and represents 15-20% of pediatric ALL cases [1]. Even with highly intensified therapy, 25% of T-ALL patients experience relapse and have lower post-relapse survival compared to the B-lineage ALL [1]. The genetic heterogeneity of the disease makes T-ALL risk stratification difficult and hence all cases are treated upfront as high-risk with intensified therapy regimen. The high dose multi-agent chemotherapy is often associated with severe toxicities and long-term side effects. Thus, improving understanding of T-ALL biology through the identification and characterization of carcinogenic lesions is essential for better prognostic classification and treatment of the disease. 

With the advent of next-generation sequencing techniques, many genetic abnormalities have been found in T-ALL over the last few decades. Aberrant expression of genes such as LMO1, LMO2, TAL1, TLX1, TLX3, NKX2-1 and other transcription factors (TFs) have long been known [2]. Whole-exome sequencing (WES), and RNA sequencing (RNA-seq) have extended the list of genetic abnormalities in T-ALL [3, 4]. Besides aberrant expression that constitutes about 40-50% T-ALL [5], RNA seq data has expanded the fusion gene list (30-40%) in T-ALL. Such fusion transcripts can either generate an over-expressing protein as in the case of TAL1 as a result of STIL::TAL1 fusion [6, 7] or lead to over-expression of two truncated peptides such as SET&NUP214 in SET:: NUP214 fusion [8]. A number a novel fusion transcripts have been also identified in studies from different cohorts such as ZBTB16::ABL1, RCBTB2::LPAR6, DLEU2::SPRYD7, TRAC::SOX8 etc. [9, 10]. Further, in a holistic approach WES along with RNA seq has identified number of gene abnormalities in pathways regulating differentiation, proliferation, self-renewal, and survival of T-cell precursors. High mutation frequencies such as NOTCH1, JAK-STAT, PI3K-AKT or RAS-MAPK pathway genes have been noted in multiple studies although the frequency varies among cohorts and population being adult or pediatric [11, 12]. Moreover, copy number variations (CNVs), especially high frequency of CDKN2A/ CDKN2B deletions have been consistently shown across multiple studies [13] [14] [15]. 

Thus, the complex interplay of gene fusions, sequence aberrations and transcriptional expression profiles needs to be increasingly investigated in different cohorts to further refine current models of T-cell leukemia and to identify potential new biomarkers and therapeutic targets. In the current study, RNA-seq and WES analyses were performed in a prospective cohort of pediatric T-ALL cases. A number of rare gene fusions, mutations, aberrant transcripts, and CNVs were identified. Overall, our results point to the need for further large-scale genomic studies to improve patient stratification and optimize treatment strategies for pediatric T-ALL, especially in relation to our distinctly ethnic sub-continental population.
section_name: Introduction

section_name: Materials and methods

section_content: Newly diagnosed pediatric T-ALL cases (age ≤12 years) confirmed on morphology and immunophenotype (flow cytometry) were enrolled for the study. Cases were classified immunophenotypically by flow cytometry into immature (pro T-and pre T-), cortical and mature T-ALL based on the EGIL criteria [16]. ETP-ALL was recognized based on the previously defined criteria [17]. Complete immunophenotype data in 3 patients was unavailable. Patients were considered as good prednisolone responder at day 8 if absolute blast counts (ABC) were < 1000/ul and poor prednisolone responder if ABC > 1000/ul. Day 8 ABC data was unavailable in6 cases. Patients were treated and followed up uniformly as per the ICiCLe treatment protocol (Clinical Trials Registry-India number, CTRI/2015/12/006,434) [18]. Written informed consent in agreement with the Declaration of Helsinki was taken from children and or guardians and the study was approved by the Institutional Ethics board.
section_name: Patients and samples

section_content: RNA was extracted from PBMCs isolated from patient blood/bone marrow samples by the RNA blood kit (Qiagen Inc. ) as per manufacturer's protocol. NEBNext RNA Ultra II directional protocol was used to prepare the libraries for total RNA. Paired-end whole transcriptome sequencing was performed on the Illumina NovaSeq to generate 60 M, 2 × 150 bp reads/sample. The raw reads were filtered using Trimmomatic for quality scores and adapters. Filtered reads were aligned to Human genome (hg19) using splice aware aligner HISAT2 to quantify reads mapped to each transcript. Alignment percentage of reads were in the range of 91. 7-97. 5%. Total number of uniquely mapped reads were counted using feature counts. The uniquely mapped reads were then subjected to differential gene expression using Deseq2 (supplementary data-TALL Deseq2 data).
section_name: RNA sequencing

section_content: The gene fusion studies of allsamples were carried out by detecting fusion events using two different prediction tools namely, FusionCatcher [19] and STARFusion [20]. The read alignment obtained from the above tools were considered for the event prediction. The tools provide both junction and spanning reads from the mapped bam file. The mapped reads from two different tools were considered as best hit. True fusions typically form from exon-exon fusion. The genomic coordinates were checked to ensure they were identical across tools with minimum distance between 5`gene and 3`gene. Manual review was applied to generate the final fusion gene list. Fusions were only considered for further analysis, if they were called by both the callers with at least 5 reads and were not detected in control samples. Novelty of fusions were checked on Mitelman Database of Chromosome Aberrations and Gene Fusions, and ChimerDB [21, 22]. 

Novel fusion validation: Novel fusion (ETV6::HDAC8) identified was validated by qRT-PCR using forward primer T
section_name: Gene fusion analysis

section_content: DNA was extracted from PBMCs isolated from blood/ bone marrow samples using Qiagen DNA blood mini kit (Qiagen Inc. ). The libraries were prepared by standard protocol of Illumina platform. Paired-end sequencing (2 × 101 bp read length) was performed using the Illumina HiSeq 2000/2500 platform. Exome sequencing analysis was performed using Dragen server (Illumina Inc. ). The fastq files after demultiplexing were first aligned to reference genome and then the output Sam files were converted to bam. The bam file was then sorted followed by duplicate removal, realignment and re-calibration. Variant caller based on haplotypecaller of GATK was used to generate the variant call files (vcf ). VCF files were then uploaded on GeneYX tool [23] for variant identifications, annotations and subsequent reporting.
section_name: Whole exome sequencing

section_content: Treatment outcome parameters analyzed included relapse free survival (RFS) or relapse rate (RR) -defined as time period from onset of therapy to disease relapse for those achieving complete remission with censoring at death in remission or last contact. Overall survival (OS)defined as time period from onset of therapy to death with censoring at last contact. Event free survival (EFS)defined as time period from onset of therapy to any event (relapse/death/abandonment of treatment against medical advice) with censoring at the time of event or last contact. Continuous variables were represented as mean/median (range) and categorical variables as ratio/ proportion. Chi-square test was performed for categorical variables between different clinical, hematological and treatment outcome parameters and genetic events. Survival curves (EFS, RR, OS) for overall cohort in relation to different genetic aberrations were calculated using Kaplan Meier curve and log-rank tests. A p-value of < 0. 05 was considered as significant. All statistical analysis was performed using SPSS v26. 0.
section_name: Outcome assessment and statistical analysis

section_name: Results

section_content: Twenty five cases of newly diagnosed pediatric T-ALL were enrolled for the study. The median age of the patients at diagnosis was 7 years (range 3-12 years) with male to female ratio of 11. 5:1. The median WBC count was 184. 18 × 10 9 /L (range 45-785 × 10 9 /L). Mediastinal mass was observed in 12 (48%) and bulky disease was observed in 9 (36%) patients. Immunophenotypically, 45% (10/22) 1.
section_name: Clinical characteristics of the patients

section_content: Based on RNA sequencing data we identified 14 cases (56%) with fusion genes. Eight different fusions were noted. The most common fusion event noted was STIL::TAL1 in 4 patients (16%). All 4 cases of STIL::TAL1 fusion were noted with either cortical or mature immunophenotype (3&1, respectively) as depicted in Fig. 1. The remaining 7 cases had fusions of NUP21::ABL1, TCF7::SPI1, ETV6::HDAC8, LMO1::RIC3, DIAPH1::JAK2, SETD2::CCDC12, and RCBTB2::LPAR6; one (4%) in each case. Among above fusion genes ETV6::HDAC8 has not been reported in literature earlier. Besides above fusion gene, 2 cases had KMT2A rearrangements and 1 case had MLL10 rearrangement. RNA sequencing data also revealed TCR re-arrangements in 10 (40%) cases, predominantly TRG@ in 8 cases (32%), 2 (8%) cases had TRA@ and 1 (4%) case had both TRA@ and TRB@ rearrangement.
section_name: Overview of fusion transcripts

section_content: The well-known expression marker genes in T-ALL, such as TLX2/3, LMO1, RAG1/2, NKX3-1/2, MYB, MYCN were noted to be the most common over expressed genes in our cohort (Fig. 1 ). Five patients (20%) had over-expression of TLX2 while 7 patients (28%) had over-expression of TLX 3. LMO1 gene over-expression was noted in 4 cases (16%). RAG1 and RAG 2 gene overexpression cases were also high in number (n = 16 & 20, respectively). The newly identified NKX3-1/2 were over expressed in 13 (52%) and 8 (32%) cases, respectively. 

Higher number of MYCN overexpressed cases (n = 13, 52%) were noted than MYB gene over expressed cases (n = 4, 16%). WT1 gene was over expressed in 13 (52%) cases. Other notable genes were GATA3 (n = 7, 28%), RUNX1 (n = 12, 48%) and PIK3R3 (n = 4, 16%), however their fold change compared to control cases were lower than other mentioned genes.
section_name: Gene expression analysis

section_content: T-ALL patients were screened for mutations by WES. Data was further re-analyzed for 60 genes previously known to be associated with T-cell leukemogenesis (supplementary Table 1 ). Eight out of 25 patients did not have sufficient DNA and therefore could not be processed for whole exome sequencing. Although focused analysis was done for 60 genes, only 23 genes showed missense or frameshift mutations predicted to result in amino acid change or change in protein length (Fig. 1 ). Seventeen cases that were analyzed for gene mutation had a median of 3 variants per case (range 1-6). The most commonly mutated gene was NOTCH1 with six cases (6/17, 35%) showing a pathogenic mutation. Five cases (5/6, 83%) showed single nucleotide variation (SNV), while the remaining one had frameshift insertion resulting in smaller predicted protein. Two cases had multiple mutations, SNV/s or frameshift mutation/s. Four cases (23%) showed mutation in WT1 gene. Three out of four cases harboring WT1 mutation was frameshift while one case had both SNV and a frameshift mutation. FBXW7, KRAS, PHF6 and JAK3 had variants in 3 (18%) cases each. While NRAS, PTEN, CDKN2A,FLT3 and IKZF1 genes were noted to have mutation in 2 (12%) cases each. MPL, ABL1, BCOR, CBL, CREBBP, KMT2A, KRAS, PDGFRA, SF3B1, SMC3, ATM and PAH genes harbored mutation in 1 (6%) case each. One case had overlapping mutation of KRAS and NRAS. All these genes had SNV except for CBL which had an insertion. The details of the variants, including the gene list and mutational frequency, are highlighted in supplementary Table 2.
section_name: Whole exome sequencing variations

section_content: The most common CNV noted through WES data was deletion of 9p21. 3 locus that consists primarily of CDKN2A, CDKN2B and MTAP genes. In our study cohort 15/17 cases (88. 2%) revealed deletion of CDKN2A/CDKN2B/MTAP genes (Fig. 1 ). Seven out of 15 (47%) cases had heterozygous while the remaining 8 (53%) had homozygous deletion. Only one case each for CDKN2B and MTAP did not show deletion with the loss of CDKN2A gene.
section_name: Copy number variation

section_content: Considering the cases with fusion gene aberration, two of the STIL::TAL1 fusion cases that had data available for DNA sequencing and they did not show any common gene mutations. While both the two cases with KMT2A rearrangement had either WT1 and PTEN gene mutations. The one case having NUP214::ABL1 fusion had NOTCH1 mutation. While MED12::IRF2BPL and RCBTB2::LPAR6 fusion cases were noted to have NRAS mutations. One case each of KMT2A rearrangement, TCF7::SP1, RCBTB2::LPAR6 fusion had KRAS gene mutation. DIAPH1::JAK2 fusion case had FBXW7, CDKN2A and CREBBP mutations. SETD2::CCDC12 case harboured BCOR mutation (Fig. 1 ). 

Correlations among genetic alterations were analyzed in those sub-groups with ≥ 5 cases carrying positive genetic lesions. NOTCH1 mutations were examined for any correlation with deletion of CDKN2A and overexpression of TLX2, TLX3 and NKX3-1. NOTCH1 mutation was significantly associated with TLX3
section_name: Association among subgroups of genetic alterations

section_content: Prognostic relevance among genetic alterations were analyzed for sub-groups with ≥ 4 cases carrying positive Although patients with both gene mutations showed slightly better overall survival (OS), this was not significant (supplementary Fig. 1A ). STIL::TAL1 fusion cases had better EFS and lower RR, however did not reach statistical significance (supplementary Fig. 1B ). Further, over-expression of TLX2/TLX3/LMO1/RAG1/2/NKX3-1/2/MYB/ MYCN for EFS, RR and OS revealed that patients with RAG2 over-expression showed better EFS (p = 0. 01) and OS (p = 0. 01). The OS of RAG2 over-expressed cases was 95% compared to 60% in those without over-expression (at 95% CI) for a median follow up 22 months (Fig. 2A ). 

Over-expression of MYB was noted to be associated with poor EFS (p = 0. 041) and RR (p = 0. 045). The EFS of MYB over-expressing cases were only 25% while the remaining patients were 71% (at 95% CI) as depicted in Fig. 2B. The remaining aberrantly expressed genes were not found to have any significant association with EFS, RR and OS in T-ALL patients.
section_name: Prognostic analyses related to the genetic features of pediatric T-All patients

section_content: Studying genetic alterations in T-ALL is the way forward in improving patients' diagnosis and treatment. Being a genetically heterogeneous disease, multi-genomics approach needs to be applied across different cohorts to elucidate the genetics of T-ALL leukemogenesis. Different studies have used different approach to identify prognostic markers and targets of therapy in T-ALL such as whole transcriptomics studies, whole exome sequencing, targeted DNA sequencing etc. However, no data from Indian subcontinent has been reported till date from study comprising transcriptomic and genomic sequencing. In the current pilot study, we have applied whole RNA and DNA sequencing to unravel maximum genetic alterations both at genes as well transcripts level in Indian cohort of pediatric T-ALL patients. We found that each of the 25 cases of our T-ALL study population harboured at least one major genetic abnormality, including gene fusions, CNV, recurrent gene mutation and/or aberrant expression of genes that are key to leukemogenesis. 56% (14/25) of our T-ALL cases harboured fusion genes. As expected co-occurrence of fusion genes in the same case was not observed, suggesting their role as driver mutations. Further, fusions were noted to be coexisting with either point mutations or aberrant expression suggesting their possible cooperative effects. STIL::TAL1 fusion being the most common (16%) in the current study, have been reported earlier by us and others in Indian cohort, however the frequency ranged from 18 to 27% [24, 25]. Earlier reports were based mainly on multiplex ligation dependent probe amplification assay (MLPA) or RT-PCR. We are for the first time, studying the combined genetic heterogeneity in T-ALL cases from Indian cohort by RNA Seq. 

We also noted a novel fusion of ETV6::HDAC8 in our cohort. An interesting study by Fisher MH et al. has shown that cytoplasmic localization of ETV6 due to inherited mutation leads to over-expression of HDAC3-regulated interferon response genes that predisposes to malignancy [26]. Fusions like TCF7::SPI1 and LMO1::RIC3, are also rarely reported. One case carrying TCF7::SPI1 fusion in a recent study cohort of 121 cases [27]. Interestingly we also noted one case having RCBTB2::LPAR6 fusion that has previously been reported in B-ALL and has been suggestive of partial loss of RB1 gene [9, 28]. 

In the current study we have demonstrated a number of genes with aberrant expression profile in transcription factors and related genes. The highest expression showing gene is TLX3 which was noted in 30% of cases. Cryptic translocation of t(5;14) (q35;q32), have been shown to result over-expression of TLX3 expression in pediatric T-ALL cases. Earlier studies have noted 20-25% cases of T-ALL with TLX3 rearrangement/ over-expression [29, 30]. Further, this genetic aberration is also shown to be associated with NOTCH1 mutation and/or NUP214::ABL1 amplifications [29]. Interestingly, all 7 cases with over expressed TLX3 had NOTCH1/ FBWX7 mutation. Moreover, one cases that harboured NUP214::ABL1 fusion in our subjects, had the highest expression of TLX3. Over-expression of this case was noted with the fold change of > 7000 compared to controls. Further, over-expression of TLX3 was noted to be significantly associated with NOTCH1 mutations (p = 0. 04). However, when prognostic outcome was analyzed in such cases, the result was not significant. 

Other noteworthy genes having aberrant expression in our cohort are LMO1, RAG1, RAG2, NKX3-2, NKX3-1, MYB and MYCN. Among these, RAG2 and MYB over expression showed a correlation with outcome parameters. RAG2 over expresssion showed better EFS (p = 0. 01) and OS (p = 0. 01) in pediatric T-ALL patients. A recent study in cell lines and mouse model, has shown that RAG1 and RAG2 expression in both primary and transformed thymocytes is mediated by NOTCH1 dimerization. Since many earlier studies suggest better outcome of patients with NOTCH1 mutations [31, 32], further investigation of NOTCH1-RAG2 axis in T-ALL cells may provide indirect evidence of mechanism behind better prognosis. Over-expression of MYB was also noted to associated with poor EFS (p = 0. 041) and RR (p = 0. 045). However, the case number over-expressing MYB (n = 4) was too small to draw any definite conclusion and further study in larger cohort is needed to validate the association. 

Mutational analysis of T-ALL cases revealed most frequent mutation in NOTCH1 gene as expected. Studies have shown the frequency of NOTCH1 mutation in T-ALL from 50 to 70% [33] [34] [35] while in Indian cohorts the frequency ranges from 40 to 50% [36, 37]. The lower frequency observed in current population could be due to the smaller cohort size. In our cohort the 6 cases that had NOTCH1 mutation only one had relapse but no significant association was noted with any outcome parameters. 

The frequency of PHF6 mutation noted in our study population is 12% similar to other studies describing the range of 5-19% in pediatric patients [37] [38] [39]. Somatic mutations and deletions of PHF6 in pediatric T-ALL have been reported exclusively or predominantly in males [13, 40]. In our cohort one out of 3 cases bearing PHF6 mutation was female. Further, in the present study, 3 cases that had PHF6 mutation did not have relapse or any other event in the median follow up of 22 months. 

WT1 mutations were noted in 23% of current study cohort. Earlier studies have reported relatively lower frequency in WT1 gene [13]. In addition, we noted that all 3 cases having mutation in WT1 gene coincided with mutations/deletions of NOTCH1/FBXW7 or PHF6 genes. Similar observation has been reported in an earlier study suggesting that loss of function in WT1 gene may cooperate in disease pathogenicity of T-cell leukemia [13]. 

We noted 5 cases with mutations occurring in NRAS or KRAS gene. Earlier studies have suggested NRAS mutation as an independent predictor of a poor outcome in ALL but a few other studies have shown favorable prognosis of RAS mutation in T-ALL [13]. In our cohorts 5 occurrence of NRAS-or KRAS mutation only one had relapse however, study on the larger cohort needs to be done before establishing any conclusion. Interestingly, FLT3 mutation was noted in 2 cases in our study population. As a target of therapy such mutations may contribute in personalized treatment of patients. 

CDKN2A/CDKN2B gene deletion has been most common genetic lesion in our population as reported previously by us and other groups in India [24, 25]. Similarly, in the current study population too, we noted 88% of cases (15/17) to have CDKN2A/ CDKN 2B deletion. Previous studies have shown that though it is the most common mutation in T-ALL with poor prognosis, it is suggested to be acquired during the course of leukaemia progression of T-ALL and is not a driver mutation of the cancer cells [14]. However more studies are needed to utilize this gene as prognostic marker or target of therapy in future. 

Although studies specially focused on pediatric T-ALL are scarce however, in the previous large studies based on pediatric T-ALL genomics and transcriptomic analysis, almost similar results have been reported. Masafumi et al., on analysis of 121 pediatric T-ALL patients reported similar results as our study where NOTCH1 and CDKN2A were the most frequently affected genes, they also reported USP7 gene in which we did not find any mutation. They also documented a SPI1 fusion and associated it with reduced overall survival, a finding we observed in our patient cohort too. However, we did not observe a statistically significant correlation, possibly attributable to our smaller sample size [27]. In a separate interesting study that analyzed both pediatric and adult samples, common fusions identified in the pediatric population included KMT2A, MLLT10, STIL-TAL1, and LMO2 fusions. Additionally, commonly mutated genes in this population were NOTCH1, KRAS, NRAS, and CDKN2A. These findings closely align with our results [41]. LEF1, WT1 and BCL11B copy number abnormalities were reported from the TARGET study of 2471 pediatric cancer patients whereas in our group we found CDKN2A, CDKN2B and MTAP harboring most copy number variations [42]. 

Thus, despite the major limitation of small cohort size of the study, we present relevant mutations and aberrant expression profile in pediatric T-ALL from Indian cohort. As ethnicity has been shown to be involved the variations in T-ALL genomics, our study is an addition of current genomics data sets available in pediatric T-ALL. Further, it will be interesting in future to study the non-coding mutations, such as microRNAs and lncRNAs to add to the cancer-related gene regulatory network changes underlying leukemogenesis of T-ALL.
section_name: Discussion

section_name: Supplementary Information

section_content: The online version contains supplementary material available at https://doi. org/10. 1186/s12885-024-12063-6.
section_name: Supplementary Information

section_name: Supplementary Material 1-T-ALL Deseq2 data

section_content: Author contributions M. S., P. S. and P. B. performed the experimental work, data analysis and in silico data analysis; R. T. assisted in experimental work; P. B., A. T. and S. S. enrolled patients and performed diagnosis of patients, clinical evaluation and clinical data analysis. M. S. conceptualized the study and wrote the manuscript with P. S. and P. B. All authors reviewed and edited the manuscript.
section_name: Supplementary Material 2-T-ALL WES and outcome data

section_content: The study is funded by Institutional Intramural Research Grant (PGIMER, Chandigarh, India).
section_name: Funding

section_content: All the data from current manuscript has been uploaded as supplementary files.
section_name: Data availability

section_content: The study was approved by Institutional Ethics Committee of Postgraduate Institute of Medical Education & Research, Chandigarh. Informed consent was taken from all the participants or parents.
section_name: Declarations Ethics approval and consent to participate

section_content: Not Applicable.
section_name: Consent for publication

section_content: The authors declare no competing interests.
section_name: Competing interests

section_content: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
section_name: Publisher's Note